Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq (6.75 mCi) ZK 6032924 (18F-FEDAA1106) for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimer's Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 185 MBq (5 mCi) ZK 6032924 in Healthy Volunteers
Latest Information Update: 27 Sep 2015
At a glance
- Drugs BAY 858101 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Bayer
- 05 May 2014 New trial record